> Research summary—not medical advice. This page synthesizes published research on a mechanism-level intervention. It is not a clinical recommendation.
Consult a qualified healthcare provider before making any changes to diet, supplementation, or treatment.
Contents
1. Overview2. Mechanism of Action3. Protocols and Administration4. Monitoring5. Contraindications and Risks6. ConnectionsOverview#
Fecal microbiota transplantation (FMT) transfers a complete microbial community from a healthy screened donor to a recipient, aiming to restore microbial diversity, colonization resistance, and metabolic function. It represents the most direct form of microbiome intervention—a wholesale ecological reset rather than incremental modulation.
> Clinical disclaimer: FMT carries risks of pathogen transmission (including multidrug-resistant organisms and viruses), variable engraftment, and unknown long-term consequences. Currently FDA-approved only for recurrent C. difficile infection. All other indications are investigational.
Mechanism of Action#
FMT operates through ecological restoration rather than single-target pharmacology. Colonization resistance: Donor anaerobes compete with pathogens for nutrients and attachment sites, re-establishing the competitive exclusion that antibiotics destroyed. SCFA restoration: Reintroduced Firmicutes (Faecalibacterium, Roseburia, Eubacterium) produce butyrate, propionate, and acetate—fueling colonocytes, maintaining barrier integrity, and modulating immune tolerance.
Bile acid metabolism: Donor bacteria expressing bile salt hydrolase convert primary bile acids to secondary forms (deoxycholic, lithocholic acid) that inhibit C. difficile spore germination.
Barrier repair: SCFA-driven colonocyte nutrition restores tight junction integrity, reducing translocation of LPS and microbial metabolites. Immune retraining: Diverse microbial antigens re-educate mucosal immune responses toward tolerance (Treg induction) rather than chronic inflammation.
Protocols and Administration#
| Parameter | Options | Notes |
|---|---|---|
| Delivery route | Colonoscopy, nasogastric tube, capsule (oral) | Colonoscopy has highest single-dose efficacy for CDI; capsules improving |
| Donor screening | Stool + blood panel (MDRO, HIV, HBV, HCV, parasites, C. diff) | Universal donor programs (stool banks) standardize screening |
| Donor selection | "Super-donors" with high diversity and SCFA production | Donor effects explain much of the outcome variance in UC trials |
| Dosing frequency | Single infusion (CDI) vs multi-session (UC, 5-40 infusions) | UC and other chronic conditions may require intensive protocols |
| FDA-approved products | Rebyota (rectal), Vowst (oral capsules) | For recurrent CDI only; standardized manufactured products |
Monitoring#
Engraftment: 16S rRNA or metagenomic sequencing at baseline, 1 month, 3 months to assess donor microbiota colonization. Clinical response: Condition-specific outcome measures (CDI recurrence, UC Mayo score, PD UPDRS). Adverse events: Monitor for fever, abdominal pain, bacteremia, new infections for 30 days post-FMT.
Long-term: Metabolic and autoimmune screening annually (unknown long-term donor microbiota effects on recipient metabolism).
Contraindications and Risks#
Immunocompromised patients: Risk of bacteremia and invasive infections. Absolute contraindication in severe immunosuppression (neutropenia, uncontrolled HIV). Pathogen transmission: Cases of ESBL-producing E. coli bacteremia (including one death) prompted enhanced donor screening requirements.
Unknown long-term effects: Donor microbiota may transmit metabolic phenotypes (obesity, autoimmune risk). Long-term registry data still accumulating.
Regulatory status: Investigational for all indications except recurrent CDI. IRB approval required for research use in other conditions. Antibiotic exposure: Recent broad-spectrum antibiotics in the recipient reduce engraftment.
Vancomycin taper-then-FMT protocol for CDI optimizes niche availability.
Connections#
Entities: Clostridioides difficile, Faecalibacterium prausnitzii, roseburia-spp
Concepts: colonization-resistance, Short-Chain Fatty Acids (SCFAs), barrier-integrity, Gut-Brain Axis, Bile Acid Metabolism
Related interventions: Probiotics (General) (incremental vs wholesale microbiome modulation), Mediterranean Diet (dietary SCFA promotion)
Signatures: clostridioides-difficile-infection, Ulcerative Colitis, Parkinson's Disease, Autism Spectrum Disorder, Hypertension
> Educational content, not medical advice. This page describes mechanisms by which the intervention interacts with the microbiome and metal ecology. It is not a treatment recommendation.
Clinical decisions about any intervention should be made with a qualified healthcare practitioner who knows your individual history.
Article network
Mentioned here 15
Pages linking here 2
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers
WikiBiome Deploy Bot · +28 −28
Inspect exact Git diff ↗ - published revision
ingest: 87 papers (17 endometriosis, 67 erectile dysfunction, 3 cross-condition)
WikiBiome Deploy Bot · +1 −1
Inspect exact Git diff ↗ - published revision
pre-overnight checkpoint 2026-04-18
WikiBiome Deploy Bot · +3 −3
Inspect exact Git diff ↗ - published revision
Adversarial audit fixes: confidence downgrades, disclaimers, STOP safety, entity cleanup
WikiBiome Deploy Bot · +7 −0
Inspect exact Git diff ↗ - published revision
v2 migration Priority 4: 13 interventions + 14 STOPs upgraded with cureva_status, karen_brain_primitives, evidence_level
WikiBiome Deploy Bot · +20 −0
Inspect exact Git diff ↗ - published revision
WikiBiome v2 migration: signature pages + safety fixes + gap analysis
WikiBiome Deploy Bot · +127 −0
Inspect exact Git diff ↗